TOPICAL DRUG DELIVERY FOR EFFECTIVE TREATMENT OF BACTERIAL INFECTIONS OF THE ANTERIOR SEGMENT OF THE EYE
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i5.24296Keywords:
Ocular drug delivery, Antibacterials, Ocular infectionsAbstract
Anterior parts of the eye are susceptible to infections caused by different bacterial species. The use of suitable therapeutic measures in case of ocular infections can be sight saving. The appropriate therapy depends on selecting the right antibacterial as well as an efficient drug delivery system. Despite their accessibility, topical delivery of the selected antibiotic into the anterior ocular parts is still a challenging issue due to the complex nature of the eye. Ocular therapy would be significantly improved by modifying the physicochemical properties of the drug and by prolonging its pre-corneal residence time. This review will help pharmaceutical formulators to identify different parts of the eye and the corresponding bacterial infections, ocular barriers to drug delivery, and general consideration when formulating ocular drug delivery systems for the treatment of eye infections.
Downloads
References
Thassu D, Chader GJ. Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems. Boca Raton, London, New York: Taylor & Francis; 2012.
Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12:348-60.
Addo RT. Ocular Drug Delivery: Advances, Challenges and Applications. Cham, ZG, Switzerland: Springer International Publishing; 2016.
Bandyopadhyay P, Coffey MJ, Shawer M. Development of ophthalmic formulations. Pharmaceutical Dosage Forms: Parenteral Medications. New York: Informa Healthcare; 2010. p. 254-86.
Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000;27:558-62.
Dartt DA. Regulation of mucin and fluid secretion by conjunctival epithelial cells. Prog Retin Eye Res 2002;21:555-76.
Kulkarni VS. Handbook of Non-Invasive Drug Delivery Systems: Science and Technology. Burlington: Elsevier Science; 2009.
Mitra AK. Treatise on Ocular Drug Delivery. Sharjah, U.A.E: Bentham Science Publishers; 2013.
Schmetterer L, Kiel J. Ocular Blood Flow. Berlin Heidelberg: Springer; 2012.
Stewart PA, Tuor UI. Blood-eye barriers in the rat: Correlation of ultrastructure with function. J Comp Neurol 1994;340:566-76.
Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol 1979;23:279-96.
Mitra AK. Ophthalmic Drug Delivery Systems. 2nd ed. New York: Taylor & Francis; 2003.
Shivhare R, Pathak A, Shrivastava N, Singh C, Tiwari G, Goyal R. An update review on novel advanced ocular drug delivery system. World J Pharm Pharm Sci 2012;1:545-68.
Chang JN. Recent advances in ophthalmic drug delivery. In: Kulkarni VS, editor. Handbook of Non-Invasive Drug Delivery Systems. Science and Technology. Burlington: Elsevier Science; 2009.
Goodenough DA. The crystalline lens. A system networked by gap junctional intercellular communication. Semin Cell Biol 1992;3:49-58.
Danysh BP, Duncan MK. The lens capsule. Exp Eye Res 2009;88:151-64.
Sharp SE, Driks MR. Bacterial Infections of the Eye. Topley and Wilson’s Microbiology and Microbial Infections. New York: John Wiley & Sons, Ltd; 2010.
Hejkal TW. Infections of the eye. In: Enna SJ, David BB, editors. XPharm: The Comprehensive Pharmacology Reference. New York: Elsevier; 2007. p. 1-10.
Wu XG, Xin M, Chen H, Yang LN, Jiang HR. Novel mucoadhesive polysaccharide isolated from bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis. J Pharm Pharmacol 2010;62:1152-7.
Uda T, Suzuki T, Mitani A, Tasaka Y, Kawasaki S, Mito T, et al. Ocular penetration and efficacy of levofloxacin using different drug-delivery techniques for the prevention of endophthalmitis in rabbit eyes with posterior capsule rupture. J Ocul Pharmacol Ther 2014;30:333-9.
Bucci FA Jr., An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Am J Ophthalmol 2004;137:308-12.
Wu X, Chen H, Jiang H, Xu Y, Liu T, Xu L. Prophylactic effect of topical fluoroquinolones in a rabbit model of Staphylococcus aureus endophthalmitis. J Ocul Pharmacol Ther 2012;28:186-93.
Molokhia SA, Thomas SC, Garff KJ, Mandell KJ, Wirostko BM. Anterior eye segment drug delivery systems: Current treatments and future challenges. J Ocul Pharmacol Ther 2013;29:92-105.
Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res 2016;6:735-54.
Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006;3:275-87.
Nettey H, Darko Y, Bamiro OA, Addo RT. Ocular Barriers. In: Addo RT, editor. Ocular Drug Delivery: Advances, Challenges and Applications. Cham: Springer International Publishing; 2016. p. 27-36.
Duxfield L, Sultana R, Wang R, Englebretsen V, Deo S, Rupenthal ID, et al. Ocular delivery systems for topical application of anti-infective agents. Drug Dev Ind Pharm 2016;42:1-1.
Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug delivery. J Ocul Pharmacol Ther 2016;32:67-82.
Ke TL, Cagle G, Schlech B, Lorenzetti OJ, Mattern J. Ocular bioavailability of ciprofloxacin in sustained release formulations. J Ocul Pharmacol Ther 2001;17:555-63.
Batra A, Kaur IP. Ocular Penetration Enhancers. Enhancement in Drug Delivery. Boca Raton: CRC Press; 2006.
Bozkir A, Denli ZF, Basaran B. Effect of hydroxypropyl-beta-cyclodextrin on the solubility, stability and in-vitro release of ciprofloxacin for ocular drug delivery. Acta Pol Pharm 2012;69:719-24.
Durairaj C, Kadam RS, Chandler JW, Hutcherson SL, Kompella UB. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci 2010;51:5804-16.
Yavuz B, Pehlivan SB, Unlü N. Dendrimeric systems and their applications in ocular drug delivery. Sci World J 2013;2013:732340.
Rathore MS, Majumdar DK. Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS Pharm Sci Tech 2006;7:57.
Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the gelrite gellan gum-based ocular delivery system for indomethacin. Acta Pharm 2003;53:251-61.
Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008;68:513-25.
Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 1998;6:105-12.
Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther 2013;29:106-23.
Sharma A, Taniguchi J. Review: Emerging strategies for antimicrobial drug delivery to the ocular surface: Implications for infectious keratitis. Ocul Surf 2017;15:670-9.
Moosa RM, Choonara YE, du Toit LC, Kumar P, Carmichael T, Tomar LK, et al. A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye. J Pharm Pharmacol 2014;66:490-506.
Al-Ghabeish M, Xu X, Krishnaiah YS, Rahman Z, Yang Y, Khan MA, et al. Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment. Int J Pharm 2015;495:783-91.
Xu X, Al-Ghabeish M, Rahman Z, Krishnaiah YS, Yerlikaya F, Yang Y, et al. Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments. Int J Pharm 2015;493:412-25.
Oyedele AO, John OO, Ogungbemi HO, Olateju SO. Ocular tolerance and in-vitro release of chloramphenicol in prospective eye ointment bases. Int J Pharm Pharm Sci 2015;7:306-11.
Gadhave MV, Dhondiram PS, Sopan KS, Gaikwad DD, Jadhav SJ, Vjsm’s. Formulation and evaluation of moxifloxacin ocusert. Int J Pharm Clin Res 2016;8:1610-5.
Gavini E, Bonferoni MC, Rassu G, Sandri G, Rossi S, Salis A, et al. Engineered microparticles based on drug-polymer coprecipitates for ocular-controlled delivery of ciprofloxacin: Influence of technological parameters. Drug Dev Ind Pharm 2016;42:554-62.
Andonova VY. A new direction in ophthalmic development: Nanoparticle drug delivery systems. Curr Pharm Des 2016;22:6313-29.
Balguri SP, Adelli GR, Janga KY, Bhagav P, Majumdar S. Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol. Int J Pharm 2017;529:32-43.
Hariprasad SM, Shah GK, Chi J, Prince RA. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J Cataract Refract Surg 2005;31:2142-6.
Almeida H, Amaral MH, Lobão P, Lobo JM. In situ gelling systems: A strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today 2014;19:400-12.
Ranch K, Patel H, Chavda L, Koli A, Maulvi F, Parikh RK. Development of in situ ophthalmic gel of dexamethasone sodium phosphate and chloramphenicol: A viable alternative to conventional eye drops. J Appl Pharm Sci 2017;7:101-8.
Kalam MA, Alshamsan A, Aljuffali IA, Mishra AK, Sultana Y. Delivery of gatifloxacin using microemulsion as vehicle: Formulation, evaluation, transcorneal permeation and aqueous humor drug determination. Drug Deliv 2016;23:896-907.
Dixit GR, Mathur VB. Microemulsions: Platform for improvement of solubility and dissolution of poorly soluble drugs. Asian J Pharm Clin Res 2015;8:7-17.
Hui A, Willcox M, Jones L. In vitro and in vivo evaluation of novel ciprofloxacin-releasing silicone hydrogel contact lenses. Invest Ophthalmol Vis Sci 2014;55:4896-904.
Kumar A, Tiwari BK, Sultana S, Kumar S. Formulation and optimization of ocular films of ofloxacin and ketorolac tromethamine. Pharm Res 2015;12:38-46.
Gilhotra RM, Mishra DN. Alginate-chitosan film for ocular drug delivery: Effect of surface cross-linking on film properties and characterization. Pharmazie 2008;63:576-9.
Sharma J, Sharma S, Kaura A, Durani S. Formulation and in-vitro evaluation of moxifloxacin ocular inserts. Int J Pharm Pharm Sci 2014;6:177-9.
Weng Y, Liu J, Jin S, Guo W, Liang X, Hu Z, et al. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B 2017;7:281-91.
Kadian R. Nanoparticles: A promising drug delivery approach. Asian J Pharm Clin Res 2018;11:30-5.
Hamsika M, Gowda DV, Vindru J, Moin A. Nanotechnology for ophthalmic preparations. Int J Curr Pharm Rev Res 2016;8:5-11.
Mehta P, Haj-Ahmad R, Al-Kinani A, Arshad MS, Chang MW, Alany RG, et al. Approaches in topical ocular drug delivery and developments in the use of contact lenses as drug-delivery devices. Ther Deliv 2017;8:521-41.
Otto W, Drahoslav L. Cross-linked Hydrophilic Polymers and Articles Made Therefrom. Google Patents; 1965.
Bengani LC, Hsu KH, Gause S, Chauhan A. Contact lenses as a platform for ocular drug delivery. Expert Opin Drug Deliv 2013;10:1483-96.
Tashakori-Sabzevar F, Mohajeri SA. Development of ocular drug delivery systems using molecularly imprinted soft contact lenses. Drug Dev Ind Pharm 2015;41:703-13.
Anshul S, Renu S. A review on levofloxacin in Situ-Gel formulation. Asian J Pharm Clin Res 2015;8:37-41.
Bhoyar BS, Patil AT. Formulation and evaluation of ophthalmic gel based on drug-polymer-polymer ternary interaction. Asian J Pharm Clin Res 2015;8:283-8.
Preethi GB, Narendra E. Formulation and evaluation of in situ mucoadhesive ophthalmic hydrogel for sustained delivery of pefloxacin mesylate. Int J Pharm Pharm Sci 2015;7:345-50.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
